Bofutrelvir

**Semantic type:** Pharmacologic Substance

**Definition:** A small molecule inhibitor of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) main protease (Mpro; 3C-like protease; 3CL protease; 3CLpro; nsp5 protease), with potential antiviral activity against SARS-CoV-2. Upon intravenous administration or inhalation into the lungs, bofutrelvir selectively targets, binds to, and inhibits the activity of SARS-CoV-2 Mpro. This inhibits the proteolytic cleavage of viral polyproteins, thereby inhibiting the formation of viral proteins including helicase, single-stranded-RNA-binding protein, RNA-dependent RNA polymerase, 20-O-ribose methyltransferase, endoribonuclease and exoribonuclease. This prevents viral transcription and replication. Bofutrelvir may have antiviral activity in the brain.

**Synonyms:** - 1H-Indole-2-carboxamide, N-((1S)-1-(cyclohexylmethyl)-2-(((1S)-1-formyl-2-((3S)-2-oxo-3-pyrrolidinyl)ethyl)amino)-2-oxoethyl)- - BOFUTRELVIR - DC402234 - FB 2001 - FB-2001 - FB2001 - MPI 10 - MPI-10 - MPI10 - Mpro Inhibitor 11A - N-((S)-3-Cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)-propan-2-yl)amino)propan-2-yl)-1H-indole-2-carboxamide